• Latest
  • Trending

Merck to end development of Covid-19 vaccines, cites inferior immune responses

1 month ago

NDLEA recovers 27 rifles in Niger, destroys 5 hectares of cannabis farm in Ondo

5 hours ago

JUST IN: ASUU declares indefinite strike in Taraba Varsity

5 hours ago

JUST IN: Reggae legend Bunny Wailer dies at 73

6 hours ago

Insecurity: Akeredolu directs council chairmen to set up local vigilantes

6 hours ago

Bandits again kill 6 persons in Kaduna

7 hours ago

Governors Forum visits Zamfara, felicitates with Governor Matawale

8 hours ago

NDLEA operatives seize 27 rifles from suspects in Niger State

9 hours ago

Dikwa Attack : Boko Haram insurgents pull out of Borno town – Sources

9 hours ago

Certain entities, groups are making capital out of Insecurity – NSA Monguno

9 hours ago

President of the Senate, Ahamd Lawan, charges new service chiefs to end insecurity

9 hours ago

2.5% PIB proposal is unacceptable to host communities in the Niger Delta – Governor Duoye Diri

10 hours ago

Chimamanda Adichie loses mother

10 hours ago
  • HOME
  • ADVERT RATE
  • Privacy Policy
  • CONTACT US
TVC News
  • Home
  • News
  • Business
  • Politics
  • Sports
  • Entertainment
  • Shows
  • Video
No Result
View All Result
Wednesday, March 3, 2021
Livestream
Advertise Here
TVC News
No Result
View All Result

Merck to end development of Covid-19 vaccines, cites inferior immune responses

January 25, 2021
in International
1 min read
Share on FacebookShare on Twitter

U.S Drugmaker Merck & Co has said it will end development of its two Covid-19 vaccines, and will focus pandemic research on treatments.

In a statement released on Monday, the multinational pharmaceutical company said it will record a pretax discontinuation charge in the fourth quarter for vaccine candidate V591, which it acquired with the purchase of Austrian vaccine maker Themis Bioscience, and V590, developed with nonprofit research organization IAVI.

The pharmaceutical company was late to join the race to develop a vaccine to protect against the coronavirus, which has so far killed more than 2 million people and continues to surge in many parts of the world including the United States.

In early trials, both vaccines generated immune responses that were inferior to those seen in people who had recovered from COVID-19 as well as those reported for other COVID-19 vaccines, the company said.

Merck said it will focus COVID-19 research and manufacturing efforts on two investigational medicines: MK-7110 and MK-4482, which it now calls molnupiravir.

Advertisement

Molnupiravir, which is being developed in collaboration with Ridgeback Bio, is an oral antiviral being studied in both hospital and outpatient settings.
The company added that a phase 2/3 trial of the drug is set to finish in May, but initial efficacy results are due in the first quarter and will be made public if clinically meaningful.

Tags: Covid-19Merck & CoMolnupiravirPharmaceutical Company
SendShareTweetShare

Related Posts

News

UPDATE: Nigeria takes delivery of AstraZeneca Vaccines

14 hours ago
News

Ghana receives 1st COVID-19 Vaccine Shipment through Global Sharing Program

6 days ago
News

COVID-19: Gov Bagudu commends CBOs, CSOs for sensitizing rural dwellers

1 week ago
Health

Nigeria records 662 cases of COVID-19, total now 150,908

2 weeks ago
International

Three people dead after heaviest snow in a decade hits Greece

2 weeks ago
International

Gaza receives first shipment of COVID-19 vaccine

2 weeks ago




TVC News Nigeria

© 2020 TVC News
First with Breaking News
All Rights Reserved

Navigate Site

  • HOME
  • ADVERT RATE
  • Privacy Policy
  • CONTACT US

Follow Us

No Result
View All Result
  • Home
  • News
  • Business
  • Politics
  • Sports
  • Entertainment
  • Shows
  • Video

© 2020 TVC News
First with Breaking News
All Rights Reserved

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

quality online essay writing service